spacer
home > ebr > autumn 2018 > applying affimers
PUBLICATIONS
European Biopharmaceutical Review

Applying Affimers

Pharmacokinetic (PK) assays are a key component of drug development and clinical follow-up processes, with the global PK assay service market currently valued at US $652.8 million (1). Results from PK assays are critical in all phases of drug development, and numerous decisionmaking milestones in drug development programmes rely, at least in part, on PK assay results and the exposure-response relationships based on pharmacodynamic (PD) endpoints or clinical endpoints. Companies are increasingly using data from drug monitoring assays at all stages of the development pipeline to enhance the productivity and efficiency of new drug development processes (2).

Both PK and PD assays require critical reagents (eg, anti-drug reagents/anti-idiotypic binders) that can specifically and accurately measure the drug in plasma and tissues. Sensitive and reproducible PK assays are required as part of the complex and lengthy development process for new therapeutic molecules. These drug monitoring assays must be well-characterised, fully validated, and documented to yield reliable results compliant with the necessary regulatory standards.

Antibodies currently represent the ‘gold standard’ of affinity reagents, and, while traditional antibodies have been refined to the point where they are specific, sensitive, and reasonably reliable, these can be limited by development speed, complexity to produce on an industrial scale, and lotto- lot variation in assay performance.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Amanda Nicholl is Senior Assay Development Scientist at Avacta, where she applies her experience in molecular and cellular biology in both academic and industrial environments to develop assays and generate data to exemplify the use of affimer technology.
spacer
Dr Amanda Nicholl
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinical and Regulatory Operational Excellence Forum

1. Innovative technologies are expected to take clinical development, licensing, and other regulatory processes to the next level in the future. What do you see are the biggest challenges facing companies when trying to cope with continued data growth in a fast changing environment? Pharmaceutical companies are heavily regulated and introducing change needs proof of acceptance by the authorities. The chance that authorities do not agree with that change makes the industry risk averse. Changes in a stable GxP environment are almost by default seen as a risk, however, not adapting to new technologies should also be seen as a risk! Therefore, ICH developed the ICH Q8, Q9, Q10, Q11, and Q12 guidelines, to anticipate change and implement changes much faster, with less of a regulatory burden. Nevertheless, industry is not picking up with the desired pace. Why not?
More info >>

White Papers

Blockbuster Drugs Need Blockbuster Components

West Pharmaceutical Services, Inc.

Many of the world’s blockbuster drugs are now delivered via a prefilled syringe system or auto-injector. To ensure patient safety, pharmaceutical manufacturers need high-quality components that feature reduced particulates and ensure consistency of delivery while fitting the changing needs of higher-volume delivery systems.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement